{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:21:15Z","timestamp":1768929675018,"version":"3.49.0"},"reference-count":37,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.4418","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T22:08:18Z","timestamp":1462054098000},"page":"1143-1147","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist"],"prefix":"10.2169","volume":"55","author":[{"given":"Hiroyo","family":"Ninomiya","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Kozawa","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takekazu","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiro","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuyuki","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Imagawa","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Kaneto","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Funahashi","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan"},{"name":"Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Odawara M, Sasaki K, Yamashita K. Prevalence and clinical characterization of Japanese diabetes mellitus with an A-to-G mutation at nucleotide 3243 of the mitochondrial tRNA<sup>Leu(UUR)<\/sup> gene. J Clin Endocrinol Metab 80: 1290-1294, 1995.","DOI":"10.1210\/jcem.80.4.7714102"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kadowaki T, Kadowaki H, Mori Y, et al. A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 330: 962-968, 1994.","DOI":"10.1056\/NEJM199404073301403"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Oka Y, Katagiri H, Ishihara H, Asano T, Kobayashi T, Kikuchi M. Beta-cell loss and glucose induced signalling defects in diabetes mellitus caused by mitochondrial tRNALeu(UUR) gene mutation. Diabet Med 13 (9 Suppl 6): S98-S102, 1996.","DOI":"10.1002\/dme.1996.13.s6.98"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Murphy R, Turnbull DM, Walker M, Hattersley AT. Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A&gt;G mitochondrial point mutation. Diabet Med 25: 383-399, 2008.","DOI":"10.1111\/j.1464-5491.2008.02359.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lynn S, Borthwick GM, Charnley RM, Walker M, Turnbull DM. Heteroplasmic ratio of the A3243G mitochondrial DNA mutation in single pancreatic beta cells. Diabetologia 46: 296-299, 2003.","DOI":"10.1007\/s00125-002-1018-z"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Naing A, Kenchaiah M, Krishnan B, et al. Maternally inherited diabetes and deafness (MIDD): Diagnosis and management. J Diabetes Complications 28: 542-546, 2014.","DOI":"10.1016\/j.jdiacomp.2014.03.006"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. de Andrade PB, Rubi B, Frigerio F, van den Ouweland JM, Maassen JA, Maechler P. Diabetes-associated mitochondrial DNA mutation A3243G impairs cellular metabolic pathways necessary for beta cell function. Diabetologia 49: 1816-1826, 2006.","DOI":"10.1007\/s00125-006-0301-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Rorsman P. The pancreatic beta-cell as a fuel sensor: an electrophysiologist's viewpoint. Diabetologia 40: 487-495, 1997.","DOI":"10.1007\/s001250050706"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lindroos MM, Majamaa K, Tura A, et al. m.3243A&gt;G mutation in mitochondrial DNA leads to decreased insulin sensitivity in skeletal muscle and to progressive beta-cell dysfunction. Diabetes 58: 543-549, 2009.","DOI":"10.2337\/db08-0981"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lindroos MM, Borra R, Mononen N, et al. Mitochondrial diabetes is associated with insulin resistance in subcutaneous adipose tissue but not with increased liver fat content. J Inherit Metab Dis 34: 1205-1212, 2011.","DOI":"10.1007\/s10545-011-9338-0"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. McKenzie D, Bua E, McKiernan S, Cao Z, Aiken JM, Jonathan W. Mitochondrial DNA deletion mutations: a causal role in sarcopenia. Eur J Biochem 269: 2010-2015, 2002.","DOI":"10.1046\/j.1432-1033.2002.02867.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Koh EH, Park JY, Park HS, et al. Essential role of mitochondrial function in adiponectin synthesis in adipocytes. Diabetes 56: 2973-2981, 2007.","DOI":"10.2337\/db07-0510"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wang CH, Wang CC, Huang HC, Wei YH. Mitochondrial dysfunction leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes. FEBS J 280: 1039-1050, 2013.","DOI":"10.1111\/febs.12096"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bijlsma AY, Meskers CG, van Heemst D, Westendorp RG, de Craen AJ, Maier AB. Diagnostic criteria for sarcopenia relate differently to insulin resistance. Age (Dordr) 35: 2367-2375, 2013.","DOI":"10.1007\/s11357-013-9516-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ishida H, Takizawa M, Ozawa S, et al. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db\/db mice: Possible protection of beta cells from oxidative stress. Metabolism 53: 488-494, 2004.","DOI":"10.1016\/j.metabol.2003.11.021"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Martin A, Perez-Giron JV, Hernanz R, et al. Peroxisome proliferator-activated receptor-gamma activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress. J Hypertens 30: 315-326, 2012.","DOI":"10.1097\/HJH.0b013e32834f043b"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 89: 4312-4319, 2004.","DOI":"10.1210\/jc.2004-0190"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 10: 1204-1211, 2008.","DOI":"10.1111\/j.1463-1326.2008.00880.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ryo M, Maeda K, Onda T, et al. A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care 28: 451-453, 2005.","DOI":"10.2337\/diacare.28.2.451"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Baumgartner RN. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147: 755-763, 1998.","DOI":"10.1093\/oxfordjournals.aje.a009520"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Takahara M, Katakami N, Kaneto H, Noguchi M, Shimomura I. Prediction of the presence of insulin resistance using general health checkup data in Japanese employees with metabolic risk factors. J Atheroscler Thromb 21: 38-48, 2014.","DOI":"10.5551\/jat.18622"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing - Comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.","DOI":"10.2337\/diacare.22.9.1462"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 371: 1131-1141, 2014.","DOI":"10.1056\/NEJMra1011035"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and imflammation. Curr Diab Rep 13: 435-444, 2013.","DOI":"10.1007\/s11892-013-0375-y"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Mitochondrial Medicine Society's Committee on Diagnosis; Haas RH, Parikh S, Falk MJ, et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab 94: 16-37, 2008.","DOI":"10.1016\/j.ymgme.2007.11.018"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 68: 975-981, 2004.","DOI":"10.1253\/circj.68.975"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Hiramatsu S, Tajiri Y, Karashima T. Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients. Diabetes Obes Metab 6: 231-233, 2004.","DOI":"10.1111\/j.1462-8902.2004.00333.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Campbell IW, Mariz S. Beta-cell preservation with thiazolidinediones. Diabetes Res Clin Pract 76: 163-176, 2007.","DOI":"10.1016\/j.diabres.2006.08.015"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Decker M, Hofflich H, Elias AN. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. Diabetes Obes Metab 10: 617-625, 2008.","DOI":"10.1111\/j.1463-1326.2007.00745.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kawasaki F, Matsuda M, Kanda Y, Inoue H, Kaku K. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db\/db mice. Am J Physiol Endocrinol Metab 288: E510-E518, 2005.","DOI":"10.1152\/ajpendo.00128.2004"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 89: 5059-5066, 2004.","DOI":"10.1210\/jc.2004-0446"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Otabe S, Yasuda K, Mori Y, et al. Molecular and histological evaluation of pancreata from patients with a mitochondrial gene mutation associated with impaired insulin secretion. Biochem Biophys Res Commun 259: 149-156, 1999.","DOI":"10.1006\/bbrc.1999.0650"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Jeppesen TD, Schwartz M, Frederiksen AL, Wibrand F, Olsen DB, Vissing J. Muscle phenotype and mutation load in 51 persons with the 3243A&gt;G mitochondrial DNA mutation. Arch Neurol 63: 1701-1706, 2006.","DOI":"10.1001\/archneur.63.12.1701"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Katagiri H, Asano T, Ishihara H, et al. Mitochondorial diabetes mellitus: prevalence and clinical characterization of diabetes due to mitochondrial tRNA<sup>Leu(UUR)<\/sup> gene mutation in Japanese patients. Diabetologia 37: 504-510, 1994.","DOI":"10.1007\/s001250050139"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Momiyama Y, Atsumi Y, Ohsuzu F, et al. Rapid progression of cardiomyopathy in mitochondrial diabetes. Jpn Circ J 63: 130-132, 1999.","DOI":"10.1253\/jcj.63.130"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108: 2941-2948, 2003.","DOI":"10.1161\/01.CIR.0000103683.99399.7E"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Beltowski J, Rachanczyk J, Wlodarczyk M. Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms. PPAR Res 2013: 628, 2013.","DOI":"10.1155\/2013\/628628"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/9\/55_55.4418\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T06:01:51Z","timestamp":1567836111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/9\/55_55.4418\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.4418","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}